TRX Stock Overview
A medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tissue Regenix Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.59 |
| 52 Week High | UK£0.75 |
| 52 Week Low | UK£0.50 |
| Beta | 1.63 |
| 1 Month Change | -0.83% |
| 3 Month Change | -0.83% |
| 1 Year Change | 9.17% |
| 3 Year Change | 12.26% |
| 5 Year Change | -38.97% |
| Change since IPO | -93.20% |
Recent News & Updates
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Recent updates
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry
Feb 25Is Tissue Regenix Group (LON:TRX) A Risky Investment?
Jun 10Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Apr 02Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Nov 18
Shareholder Returns
| TRX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.6% | -3.2% | -1.5% |
| 1Y | 9.2% | -21.4% | 3.5% |
Return vs Industry: TRX exceeded the UK Biotechs industry which returned -21.4% over the past year.
Return vs Market: TRX exceeded the UK Market which returned 3.5% over the past year.
Price Volatility
| TRX volatility | |
|---|---|
| TRX Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TRX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: TRX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 82 | Danny Lee | www.tissueregenix.com |
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.
Tissue Regenix Group plc Fundamentals Summary
| TRX fundamental statistics | |
|---|---|
| Market cap | UK£42.38m |
| Earnings (TTM) | -UK£871.77k |
| Revenue (TTM) | UK£25.18m |
1.7x
P/S Ratio-48.6x
P/E RatioIs TRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRX income statement (TTM) | |
|---|---|
| Revenue | US$31.80m |
| Cost of Revenue | US$16.06m |
| Gross Profit | US$15.73m |
| Other Expenses | US$16.84m |
| Earnings | -US$1.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 49.48% |
| Net Profit Margin | -3.46% |
| Debt/Equity Ratio | 34.9% |
How did TRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 18:46 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tissue Regenix Group plc is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Brewer | Cavendish |
| Christopher Donnellan | Cavendish |
| Vadim Alexandre Khalil | Daniel Stewart & Company |